Efficacy and tolerability of three topical acne treatments by body mass index: post hoc analysis including overweight and obese patients

Efficacy and tolerability of three topical acne treatments by body mass index: post hoc analysis including overweight and obese patients

Background Acne prevalence may be higher in overweight/obese individuals, potentially due to hormonal, inflammatory, and/or dietary factors. However, the effects of body mass index (BMI) on topical acne treatments are largely unknown. Methods Post hoc analyses of changes in inflammatory/noninflammat...

Full description

Bibliographic Details
Main Authors: Jonette Keri, Fran E. Cook-Bolden, Lawrence Green, Leon H. Kircik, Hilary Baldwin, William Philip Werschler, Eric Guenin, Radhakrishnan Pillai, Varsha Bhatt
Format: Article
Language:English
Published: Taylor & Francis Group 2022-08-01
Series:Journal of Dermatological Treatment
Subjects:
topical
acne
bmi
retinoid
antibiotic
phase 3
tazarotene
tretinoin
clindamycin phosphate
benzoyl peroxide
Online Access:http://dx.doi.org/10.1080/09546634.2022.2071823
Description
Summary:Background Acne prevalence may be higher in overweight/obese individuals, potentially due to hormonal, inflammatory, and/or dietary factors. However, the effects of body mass index (BMI) on topical acne treatments are largely unknown. Methods Post hoc analyses of changes in inflammatory/noninflammatory lesions and treatment success were conducted using phase 3 data: clindamycin phosphate/benzoyl peroxide (CP/BPO) 1.2%/3.75% gel (NCT01701024); tretinoin 0.05% lotion (NCT02965456 and NCT02932306; pooled); and tazarotene 0.045% lotion (NCT03168321 and NCT03168334; pooled). Data were analyzed by BMI subgroups: <25kg/m2 (underweight-to-normal), 25-<30kg/m2 (overweight), and ≥30kg/m2 (obese). Results Among participants analyzed (CP/BPO = 495; tretinoin = 1,636; tazarotene = 1,612), ∼20–25% were overweight and 15–20% were obese. At week 12, mean percent changes from baseline in inflammatory lesions were: CP/BPO (overweight: −63.2%, obese: −56.0%); tretinoin (−57.6%, −53.1%); tazarotene (−59.9%, −56.8%). Mean changes in noninflammatory lesions were: CP/BPO (−54.2%, −50.8%); tretinoin (−51.6%, −44.9%); tazarotene (−56.7%, −54.6%). Treatment success rates with active treatment ranged from 16.2% to 33.5% across BMI groups. Conclusions CP/BPO 1.2%/3.75% gel, tretinoin 0.05% lotion, and tazarotene 0.045% lotion were all effective in reducing acne lesions by ≥45% in overweight/obese patients with moderate-to-severe acne, comparable to the underweight-to-normal group. Efficacy of these topical acne treatments is not greatly impacted by BMI and may be affected more by the formulation.
ISSN:0954-6634
1471-1753

Similar Items